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Aquaporin-1 transports nitric 
oxide across cell membranes
Nitric oxide (NO) plays an important role in the regulation of 
blood pressure through its eff ects on the kidney, vasculature, and 
central nervous system. In the kidney, it may promote natriuresis 
and diuresis via its eff ects on glomerular fi ltration, salt and water 
absorption along the nephron, and tubuloglomerular feedback. 
NO can also reduce blood pressure by dilating vessels in the 
vasculature and acts as a neurotransmitter in the brain. How NO 
exits and enters cells is unclear, but it has been thought to freely 
diff use through the lipid bilayer.
Although the role of aquaporin-1 (AQP-1) in water 
transport across some cells, such as the renal epithelium, is 
best understood, this channel has also been shown to transport 
small gas molecules such as carbon dioxide and ammonia. 
Because AQP-1 is highly expressed in cells that produce NO, 
Herrera et al. investigated whether AQP-1 transports NO 
across cell membranes. Th ey found that in cells expressing 
AQP-1, NO permeability correlated with water permeability 
and NO transport was markedly reduced by HgCl2, an 
inhibitor of AQP-1. Transport of NO by AQP-1 was saturable at 
micromolar concentrations. Further, reconstitution of purifi ed 
AQP-1 into lipid vesicles increased NO infl ux by approximately 
300%. In endothelial cells, lowering AQP-1 expression with 
a small interfering RNA blunted AQP-1 expression and NO 
release by about half. Th e authors conclude that NO transport 
by AQP-1 may allow cells to control intracellular NO levels 
and eff ects, and that alterations of NO transport by AQP-1 
may be a cause for diseases with inadequate NO bioavailability. 
(Hypertension 2006; 48: 157–164)
Juan Oliver
A role for ACE2 in blood pressure 
regulation
Angiotensin-converting enzyme (ACE) plays a critical role in 
production of angiotensin II (Ang II). Th ere are two distinct 
forms of ACE, both generated by alternative splicing of a single 
gene. With the use of genome-based strategies, homologues 
of ACE have been identifi ed. One of these, ACE2, exhibits 
more than 40% identity at the protein level with the catalytic 
domain of ACE. Like ACE, ACE2 is expressed on the surface 
of certain endothelial-cell populations. However, as compared 
with the ubiquitous distribution of ACE, the expression pattern 
of ACE2 is more limited, with the most abundant expression 
in the kidney, followed by the heart and testis. Th eir substrate 
specifi cities also diff er; ACE2 hydrolyzes Ang II with high 
effi  ciency but has much lower activity against Ang I. ACE2 was 
originally identifi ed and cloned from a cDNA library prepared 
from the ventricular tissue of a patient with heart failure; high 
levels of ACE2 expression in the heart and kidney suggest 
a potential role in cardiovascular regulation. To examine 
the role of ACE2, Gurley et al. induced targeted disruption 
of the Ace2 gene in mice. Th ey found that ACE2-defi cient 
mice were viable and fertile and lacked any gross structural 
abnormalities. Cardiac dimensions and function were normal 
in ACE2-defi cient animals with mixed or inbred genetic 
backgrounds. On the C57BL/6 background, ACE2 defi ciency 
was associated with a modest increase in blood pressure, but 
in 129/SvEv mice, blood pressure was normal. However, acute 
Ang II infusion induced much higher plasma concentrations 
of Ang II in ACE2-defi cient mice than in controls (see Figure). 
During infusion of exogenous Ang II, blood pressures were 
substantially higher in the ACE2-defi cient mice than in the 
wild type. Hence, ACE2 is a functional component of the 
renin–angiotensin system, metabolizing Ang II and thereby 
contributing to regulation of blood pressure. Further, the 
absence of functional ACE2 increases susceptibility to Ang II-
induced hypertension. (J Clin Invest 2006; 116: 2218–2225)
Juan Oliver
The glomerular basement 
membrane is a barrier to albumin
Th e cardinal feature of nephrotic syndrome is severe 
proteinuria resulting from increased fl ux of albumin and other 
plasma proteins across the glomerular fi ltration barrier. Th e role 
of the glomerular basement membrane (GBM) in glomerular 
permselectivity, if any, is not clear and is now considered 
secondary to that of the podocyte slit diaphragm. Nevertheless, 
proteinuria can result from either primary podocyte or 
primary GBM defects, so how a GBM defect might cause 
proteinuria is still unclear. Some investigators have suggested 
podocyte detachment from the GBM as a possible explanation. 
Another possibility is that abnormal matrix components signal 
anomalously via podocyte cell surface receptors and disrupt 
podocyte homeostasis. Finally, the last theory is that the GBM 
is a major factor in determining glomerular permselectivity, 
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Administration of exogenous Ang II resulted in much higher plasma 
levels in ACE2-deficient mice than in controls.
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acting as a modifi ed gel through which macromolecules such as 
albumin pass primarily by diff usion, independent of fl uid fl ow 
(the gel permeation/diff usion hypothesis).
Laminin β2 (LAMB2) is a GBM component required 
for proper functioning of the glomerular fi ltration barrier; 
children with mutations of its gene may present with congenital 
nephrotic syndrome. In a new study, Jarad et al. investigated 
the role of the GBM in glomerular function by characterizing 
the GBM and overlying podocyte architecture during 
development and progression of proteinuria in Lamb2–/– mice. 
Th ey found ectopic deposition of several laminins and mis-
localization of anionic sites in the GBM, which indicates that 
the Lamb2–/– GBM  was severely disorganized, although it 
was ultrastructurally intact. Importantly, albuminuria was 
detected shortly aft er birth and preceded podocyte foot process 
eff acement (see Figure) and loss of slit diaphragms by at least a 
week. Expression and localization of slit diaphragm- and foot 
process-associated proteins appeared normal at early stages. 
GBM permeability to the electron-dense tracer ferritin was 
dramatically elevated in Lamb2–/– mice, even before widespread 
foot process eff acement. Increased ferritin permeability was not 
observed in nephrotic CD2-associated protein-null (Cd2ap–/–) 
mice, which had a primary podocyte defect. Together, these 
results show that the GBM serves as a barrier to protein in vivo, 
and that the glomerular slit diaphragm alone is not suffi  cient to 
prevent the passage of albumin into the urinary space. (J Clin 
Invest 2006; 116: 2272–2279)
Juan Oliver
Continuous venovenous 
hemodiafiltration versus 
intermittent hemodialysis for 
acute renal failure
Continuous renal replacement therapy (CRRT) is an 
alternative to intermittent hemodialysis in critically ill 
patients with acute kidney injury, especially those who are 
hemodynamically unstable. Some clinicians consider CRRT 
to have many advantages over intermittent dialysis. However, 
evidence of the superiority of CRRT is scarce. In a new study, 
Vinsonneau and colleagues showed that almost all patients 
with acute renal failure as part of multiple-organ dysfunction 
syndrome can be treated with intermittent hemodialysis, 
provided that strict guidelines to improve tolerance and 
metabolic control are used.1 Th is prospective, randomized, 
multicenter study may have been biased toward intermittent 
hemodialysis, in view of remarkable diff erences in the 
crossover from one treatment to the other. Furthermore, 
the dose of therapy is not specifi ed in the protocol in either 
treatment arm, and the delivered doses in both arms might 
have been less than optimal. Nevertheless, the study by 
Vinsonneau et al. suggests that improved survival depends on 
how renal support is provided, as shown by the improvement 
over time in the intermittent-hemodialysis arm. A comment 
by Kellum and Palevsky discusses the pros and cons of CRRT 
in hemodynamically unstable patients.2 Whether intermittent 
dialysis is as good as or better than CRRT cannot be answered 
by this study, given its limited statistical power. Th e answer 
to this question has yet to be determined. (1Lancet 2006; 368: 
379–385. 2Lancet 2006; 368: 344–345)
Marc De Broe
Proteinuria precedes foot process effacement in Lamb2–/– glomeruli in 2-
day-old (top) and 5-day-old (middle) mice. Left lanes, normal; right lanes, 
Lamb2–/– littermates.
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